Peptora
← All peptides

SLU-PP-332

★ 55

Saint Louis University Pan-ERR Agonist 332

Exercise-mimetic ERR agonist for endurance and fat loss

Fat Loss
Half-life
Not formally established in humans; measurable plasma and muscle levels at 6 hours in mice (supports BID preclinical dosing)
Route
Oral
Cycle
6-8 week cycles
Status
Preclinical only — no human pharmacokinetic or safety data

About

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ), nuclear receptors that drive mitochondrial biogenesis and oxidative metabolism. By directly activating the same transcriptional program triggered by endurance exercise, it raises oxidative muscle fiber content and energy expenditure without mechanical loading. It is approximately 4-fold more potent at ERRα than ERRγ, favoring muscle and metabolic tissue effects. Despite striking rodent efficacy, no human trials exist as of 2026.

Mechanism

Pan-agonism of ERRα/β/γ nuclear receptors increases mitochondrial biogenesis, fatty-acid oxidation, and type IIa oxidative muscle-fiber formation — reproducing the transcriptional signature of aerobic exercise.

Dosage

beginner

Amount
12.5-25 mg
Frequency
1x per day
Route
Oral
Duration
4 weeks

standard

Amount
50 mg
Frequency
1x per day
Route
Oral
Duration
6-8 weeks

advanced

Amount
50 mg 2x/day or 100 mg 1x/day
Frequency
1-2x per day
Route
Oral (community SubQ 250 mcg-1.5 mg also reported)
Duration
8-12 weeks
Timing

Morning dosing preferred to avoid sleep disruption from stimulatory effects. BID protocols split morning and early afternoon.

Cycle structure

6-8 week cycles aligned with published chronic mouse studies; 4-week breaks recommended between cycles.

Reconstitution & Storage

5 mg + 2 mL → 2500 mcg/mL

Inject BAC water slowly down vial wall; swirl gently. Protect reconstituted solution from light — deepening yellow color indicates oxidation, replace if observed.

Lyophilized: months refrigerated, longer at -20°C. Reconstituted: 2-8°C light-protected, 2-4 weeks. Oral tablets: room temperature, dry, dark.

Benefits

  • • 25-30% fat-mass reduction in diet-induced obese mice (28 days)
  • • Increased treadmill endurance and oxidative muscle fiber content
  • • Improved glucose tolerance without altered food intake
  • • Improved cardiac ejection fraction in heart-failure mouse models
  • • Restored mitochondrial function in aging kidney models

Side effects

  • • Sleep disruption and stimulatory effects
  • • Increased resting heart rate
  • • Appetite changes (community reports)
  • • Unknown chronic cardiovascular risk
  • • Uncertain cancer-metabolism interactions (ERRα implicated in some tumor pathways)

Contraindications

  • • Pregnancy and breastfeeding
  • • Age under 18
  • • Active or recent cancer history
  • • Cardiovascular disease, arrhythmia, uncontrolled hypertension
  • • Significant liver or kidney impairment
  • • WADA-tested competitive athletes (falls under S4.5 metabolic modulators)
  • • Concurrent stimulants without clinical oversight

Gender notes

Men

Standard dosing applies. Popular in endurance and body-recomposition stacks.

Women

Standard dosing applies. ERR receptors are not estrogen receptors despite the name — no direct hormonal effect, but no female-specific human data exists.

Research

Stacks well with

MOTS-C 5-AMINO-1MQ AOD-9604 TESAMORELIN

Track SLU-PP-332 doses in the app

Built-in reconstitution calculator, dose log, and reminders. Free on Android.

Get on Google Play

Educational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.